New York (March 28th, 2013) - MGIC Investment Corp. (NYSE: MTG) traded in the range of $4.55 and $4.89 during its latest trading session. The stock had opened at $4.56 and is currently at $4.83, up 5 percent from its previous close. MGIC Investment recorded the volume of 12.87 million shares, in comparison to its average daily trading volume of 27.38 million shares, thus showing bullish trend. The stock has overall bullish trend as per its MACD chart and the stock is likely to maintain the streak.
MGIC Investment is likely to touch $4.95 price level in the coming trading sessions. The company provides private mortgage insurance services.
Ziopharm Oncology Inc. (NASDAQ: ZIOP) opened at $1.70 and oscillated in the range of $1.68 and $1.86 in the latest trading session. It is at $1.80, up 4.08 percent from its previous close. Ziopharm Oncology shows bullish trend and the stock’s first resistance level is at $1.86. Upon breaching this level, the stock may touch $1.90. On the downside, it may slip to $1.70. It has traded3.18 million shares, higher than its usual trading volume of 2.91 million shares. The stock has lost 57 percent of its value in 2013 so far.
Ziopharm Oncology develops and markets cancer therapies.
Find out more on ZIOP here:
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: www.wallstreetreport.net/disclaimer-2/